Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.36 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21844539 | 0.98 | EPHX1 (0.43) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL26718738 | 0.94 | GNAI3 (0.37) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL3686292 | 0.87 | EPHX1 (0.50) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL3140310 | 0.87 | EPHX1 (0.50) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL19993065 | 0.87 | GNAI3 (0.41) | CYP1A2CYP2D6CYP2C19GNAI3GNAO1 | |
| SCHEMBL23348055 | 0.87 | EPHX1 (0.50) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL24115531 | 0.87 | EPHX1 (0.50) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL13964480 | 0.87 | EPHX1 (0.50) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL26069 | 0.87 | EPHX1 (0.50) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL1356285 | 0.85 | EPHX1 (0.48) | EPHX1KDM4EALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210030832-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030832-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | EPHX1 2162/4885KDM4E 703/4885ALDH1A1 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.